Skip to main content

Clinical Trials Using Atezolizumab

Review the clinical trials studying atezolizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-97 of 97

Pemigatinib and Atezolizumab With or Without Bevacizumab for Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
NBTXR3, Radiation Therapy, and Immunotherapy (Anti-PD-1/L-1) for the Treatment of Lung and/or Liver or Soft Tissue Metastases from Solid Malignancy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Total Body Irradiation and Hypofractionated Radiation Therapy with Atezolizumab and Chemotherapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, TESSERACT Trial
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Split Course Adaptive Radiation Therapy and Immunotherapy with or without Chemotherapy for the Treatment of Stage IV or Locally Advanced Lung Cancer, SiCARIO Study
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Radiotherapy in Combination with Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous Squamous Cell Carcinoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Combination ONC201 and Atezolizumab for the Treatment of Metastatic or Recurrent Obesity-Driven Endometrial Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
Status: Active
Location: See ClinicalTrials.gov
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Status: Active
Location: See ClinicalTrials.gov
Atezolizumab with Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab for the Treatment of Patients with Resectable, Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: 2 locations
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Testing Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Kidney Cancer, PAPMET2 Trial
Status: Temporarily Closed to Accrual
Location: 166 locations
Atezolizumab in Combination with Cyclophosphamide, Sorafenib, and Bevacizumab for the Treatment of Recurrent or Refractory Solid Tumors in Pediatric Patients, ANGIO-A Study
Status: Temporarily Closed to Accrual
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio